Xynomic Research Institute

Xynomic Pharmaceuticals is a clinical-stage oncology biopharmaceutical company that specialized in developing small molecule inhibitors for various cancers. The company's lead candidate, abexinostat, is a novel HDAC inhibitor that reached Phase 3 clinical trials for renal cell carcinoma in combination with pazopanib. Other notable assets in its pipeline included XP-105, a dual mTORC1/2 inhibitor, and XP-102, a RAF inhibitor licensed from Boehringer Ingelheim. Although the company successfully transitioned to the public markets via a SPAC merger in 2019, it faced significant financial challenges and was subsequently delisted from the NASDAQ. The company is currently considered inactive, with its clinical programs largely stalled.